Australia's most trusted
source of pharma news
Sunday, 08 September 2024
Posted 25 July 2024 AM
CSL Vifor has resolved its antitrust dispute with the European Commission, with a ten-year communication campaign.
Earlier this year the Australian giant offered commitments to the EC, which spent a month market testing those commitments and consulting interested third parties. Taking the outcomes of the market testing into consideration, CSL Vifor adjusted the commitments, and the EC has now accepted them and made them legally binding.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.